Floradapt Digest


Floradapt™ Digest is a symbiotic formula that helps to protect against occasional diarrhea. Its formulation contains three clinical strains that replenish and reestablish the microbiota diversity. Floradapt™ Digest has a unique dosage format — push-through cap in a single-serving, glass vial.

Floradapt™ Digest formula contains three unique strains of Pediococcus pentosaceus, Bifidobacterium longum and Lactobacillus rhamnosus GG. Its unique mechanism of action consists of:

  • Homofermentative metabolism strains selected for Floradapt™ Digest do not produce CO2
  • Recovers the positive microbiota (Bifidobacterium and Lactic Acid)
  • Contains L. rhamnosus GG which enhances GI epithelial structure and function

Promotes gastrointestinal health by different mechanisms:

  • Helps counter occasional diarrhea
  • Helps restore microbiota diversity

Enhances immune system function.

  1. Perez C. Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children. Nutr Hosp 2015; 31(Supl.1):64-67.
  2. Lozupone C et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415): 220–30.
  3. LGG Summatim. Lactobacillus GG and its health effects. http://www.clinicaleducation.org/wp-content/ uploads/LGG_Summatim_english.pdf
  4. Bien J et al. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Journal List Therapeutic Advances in Gastroenterology 2013; 6(1): 53-68.
  5. Parashar et al. Global Illness and Deaths caused by rotavirus disease in children. Emerging Infect Dis 2003; 9:565- 72.
  6. Tanaka S et al. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunol Med Microbiol 2009 Jun; 56(1):80-7.
  7. Kachrimanidou M et al. Clostridium difficile infection: New insights into therapeutic options. Crit Rev Microbiol 2016 Sep; 42(5):773-9.
  8. Santas J et al. Pediococcus pentosaceus CECT 8330 and Bifidobacterium longum CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharma Bio Sci 2015; 6(2):P458–66.
  9. Xu et al. Assessment of cell surface properties and adhesion potential of selected probiotic strains. Lett Appl Microbiol 2009; 49(4), 434-442.
  10. Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics; MEDICAL POSITION PAPER 2014.
  11. World Gastroenterology Organization Global Guideline on Probiotics and Prebiotics, February 2017.
  12. Szajewska H et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001; 138: 361-5.
  13. Canani RB et al. Probiotics for treatment of acute diarrhoea in children:randomised clinical trial of five different preparations. BMJ 2007; 335: 340-5.
  14. Szajewska H, Wanke M, Patro B. Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Aliment Pharmacol Ther. 2011 Nov;34(9):1079-87.
  15. Szajewska et al. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children updated analysis of randomised controlled trials. Alimentary Pharmacology and Therapeutics 2013; 38:467-476 https://www.ncbi.nlm.nih.gov/pubmed/23841880.
  16. Yan F et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132(2): 562-575.
  17. USAID, UNICEF, WHO.(2005). Diarrhea treatment guidelines including new recommendations for the use of ORS and zinc supplementation for clinic-based healthcare workers. Available at: http://whqlibdoc.who.int/ publications/2005/a85500.pdf?ua=1 [Access date April 2015].
  18. Patro B, Golicki D, Szajewska H. Meta-analysis: zinc supplementation for acute gastroenteritis in children. Aliment Pharmacol Ther 2008; 28(9):713–23.
  19. Varughese CA, Vakil NH, Phillips KM. Antibiotic associated diarrhea: a refresher on causes and possible prevention with probiotics–continuing education article. J Pharm Pract. 2013 Oct;26(5):476-82.
  20. Hidaka H et al. The effects of undigestible fructooligosachharides on intestinal microflora and varios physiological functions on human health. Adv Exp Med Biol 1990; 270:105-17.
  21. Saad, N, et al. An overview of the last advances in probiotic and prebiotic eld. LWT – Food Science and Technology. 2013; 50(1): 1-16.